Hims & Hers Adds Lilly’s Zepbound and Foundayo to Its Platform, Putting Lilly on Equal Footing With Novo
Hims & Hers Health (NYSE: HIMS) shares rose more than 7% in premarket trading Friday after the telehealth company and Eli Lilly announced an agreement to sell Lilly’s obesity drugs Zepbound and Foundayo directly on the Hims & Hers platform. The deal closes a gap in the company’s weight-loss lineup just three days before its third-quarter earnings report.
Key Points
- Eligible Hims & Hers patients can now get Lilly’s Zepbound and Foundayo at Lilly’s self-pay prices without leaving the platform.
- Self-pay pricing starts at $149 a month for Foundayo and $299 a month for Zepbound, matching LillyDirect.
- Hims & Hers agreed not to sell compounded or knockoff versions of Lilly’s obesity medications.
- HIMS rose more than 7% premarket ahead of Q3 earnings on November 9.
A Smoother Path From Prescription to Purchase
Under the agreement, patients who receive a prescription from a licensed provider on the Hims & Hers platform can buy Zepbound (tirzepatide) and Foundayo (orforglipron) at the same self-pay prices Lilly offers any patient. Previously, Hims & Hers users who wanted a Lilly drug had to leave the site and finish the purchase on LillyDirect, Lilly’s own cash-pay platform.
That extra step mattered. Lilly USA President Ilya Yuffa said every friction point raises the chance that a patient abandons the purchase. In addition, Lilly framed the deal as a way of “meeting patients where they already are.”
Lilly Catches Up to Novo on the Platform
The agreement also puts Lilly on equal footing with Novo Nordisk. Novo has sold Wegovy and Ozempic through Hims & Hers since March, after previously suing the company over compounded versions of its drugs. Novo’s pricing on the platform starts at $149 a month for the Wegovy pill and $199 for the Wegovy pen.
As part of the Lilly deal, Hims & Hers committed to stop selling any compounded or knockoff versions of Lilly’s obesity medications. As a result, the company now offers branded GLP-1 therapies from both major manufacturers under one roof.
Why Self-Pay Is the Battleground
Self-pay is a large and growing channel for these drugs. According to Lilly, 40% to 45% of Zepbound sales already come through self-pay channels. Meanwhile, analysts expect Hims & Hers could benefit next year as employers drop coverage of weight-loss drugs to control costs, which would push more patients toward cash-pay options.
The move follows a similar step from LifeMD, which PRISM MarketView covered yesterday when it expanded direct pharmacy access to Lilly’s self-pay GLP-1 medicines. Together, the two deals show Lilly widening its direct-to-consumer reach through telehealth partners.
Earnings Next Up
Hims & Hers reports third-quarter 2026 results after the market closes on November 9, with analysts expecting revenue of about $893 million. The Lilly partnership gives investors a fresh growth lever to weigh heading into the print. PRISM MarketView previously reported that the platform serves nearly 3 million people, as Hims & Hers highlighted growth in the peptide market, and that the company expanded into Australia with a women’s health platform.
Hims & Hers is a component of the PRISM Wellness Index. For more on companies in the obesity space, see the PRISM Weight Loss Index.
